• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Enveric Biosciences Inc.

    12/5/25 5:40:58 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENVB alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ENVERIC BIOSCIENCES, INC.

    (Name of Issuer)


    Common Stock, $0.01 par value per share

    (Title of Class of Securities)


    29405E505

    (CUSIP Number)


    12/03/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    29405E505


    1Names of Reporting Persons

    Northstrive Fund II LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    25,915.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    25,915.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    25,915.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.34 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  (1) This percentage is based on 596,978 shares of Common Stock of the Issuer that were outstanding as of November 12, 2025, as reported in the Issuer's Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") on November 14, 2025. For the avoidance of doubt, the holdings of the Reporting Persons reported herein are as of December 3, 2025. The aggregate percentage ownership of both Reporting Persons is approximately 5.01%.


    SCHEDULE 13G

    CUSIP No.
    29405E505


    1Names of Reporting Persons

    Braeden Lichti
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    4,005.00
    6Shared Voting Power

    25,915.00
    7Sole Dispositive Power

    4,005.00
    8Shared Dispositive Power

    25,915.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    29,920.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.01 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (2) This percentage is based on 596,978 shares of Common Stock of the Issuer that were outstanding as of November 12, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 14, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ENVERIC BIOSCIENCES, INC.
    (b)Address of issuer's principal executive offices:

    245 First Street, Riverview II, 18th Floor, Cambridge, MA
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Northstrive Fund II LP, a Delaware limited partnership; and (ii) Braeden Lichti ("Mr. Lichti"). The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The securities reported herein are held by Northstrive Fund II LP and Braeden Lichti. Mr. Lichti is the Manager of Northstrive Fund II LP. As such, Mr. Lichti may be deemed to beneficially own the securities held by Northstrive Fund II LP. To the extent Mr. Lichti is deemed to beneficially own such securities, Mr. Lichti disclaims beneficial ownership of these securities for all other purposes.
    (b)Address or principal business office or, if none, residence:

    120 Newport Center Drive, Suite 250 Newport Beach, CA 92660
    (c)Citizenship:

    Northstrive Fund II LP is a Delaware corporation. Mr. Lichti is a citizen of Canada.
    (d)Title of class of securities:

    Common Stock, $0.01 par value per share
    (e)CUSIP No.:

    29405E505
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Rows 5-11 of the cover page for each Reporting Person and is incorporated herein by reference for each Reporting Person.
    (b)Percent of class:

    Northstrive Fund II LP: 4.34% Braeden Lichti: 5.01%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Northstrive Fund II LP: 0 Braeden Lichti: 4,005

     (ii) Shared power to vote or to direct the vote:

    Northstrive Fund II LP: 25,915 Braeden Lichti: 25,915

     (iii) Sole power to dispose or to direct the disposition of:

    Northstrive Fund II LP: 0 Braeden Lichti: 4,005

     (iv) Shared power to dispose or to direct the disposition of:

    Northstrive Fund II LP: 25,915 Braeden Lichti: 25,915

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Northstrive Fund II LP
     
    Signature:/s/ Braeden Lichti
    Name/Title:Braeden Lichti, Manager
    Date:12/05/2025
     
    Braeden Lichti
     
    Signature:/s/ Braeden Lichti
    Name/Title:Braeden Lichti
    Date:12/05/2025
    Get the next $ENVB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENVB

    DatePrice TargetRatingAnalyst
    3/8/2022$7.00 → $0.20Buy → Hold
    Aegis Capital
    7/8/2021$7.00Buy
    Aegis Capital
    6/28/2021$6.00Buy
    Maxim Group
    More analyst ratings

    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

    RCANN™ Trademark Portfolio Out-Licensed Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that its subsidiary, Akos Biosciences, has licensed to TOTEC Pharma, Inc. ("TOTEC") its US Trademark portfolio for RCANN™ and an RCANN™ design. TOTEC, an affiliate of Aries Science & Technology ("Aries"), is advancing the commercialization of patented cannabinoid crème technology created by Enveric and intended for use in treatment of radiation dermatitis. The trademark license to TOTEC includes an option to purchase the RCANN trad

    1/29/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share. In a concurrent private placement, the Company issued unregistered series G warrants to purchase up to 328,802 shares of common stock and unregistered series H warrants to purchase up to 328,802 shares of common stock. The series G warrants have an exercise price of $4.16

    1/28/26 5:00:00 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 328,802 shares of common stock at a purchase price of $4.41 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered series G warrants to purchase up to 328,802 shares of common stock and unregistered series H warrants to purchase up to 328,802 shares of common stock. The series G warrants will have an ex

    1/28/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Dewitt Sheila was granted 7,633 shares, increasing direct ownership by 4,925% to 7,788 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    12/30/25 4:42:13 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kegler George A. was granted 7,633 shares, increasing direct ownership by 2,859% to 7,900 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    12/30/25 4:41:22 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pasqualone Frank was granted 7,633 shares, increasing direct ownership by 2,817% to 7,904 units (SEC Form 4)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    12/30/25 4:40:31 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    SEC Filings

    View All

    SEC Form D filed by Enveric Biosciences Inc.

    D - Enveric Biosciences, Inc. (0000890821) (Filer)

    2/11/26 5:00:43 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-1 filed by Enveric Biosciences Inc.

    S-1 - Enveric Biosciences, Inc. (0000890821) (Filer)

    2/9/26 9:28:52 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Enveric Biosciences, Inc. (0000890821) (Filer)

    2/6/26 4:45:30 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Enveric Biosciences downgraded by Aegis Capital with a new price target

    Aegis Capital downgraded Enveric Biosciences from Buy to Hold and set a new price target of $0.20 from $7.00 previously

    3/8/22 9:32:53 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aegis Capital initiated coverage on Enveric Biosciences with a new price target

    Aegis Capital initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $7.00

    7/8/21 9:31:19 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Enveric Biosciences with a new price target

    Maxim Group initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $6.00

    6/28/21 8:59:11 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Pasqualone Frank bought $2,140 worth of shares (1,000 units at $2.14)

    4 - Enveric Biosciences, Inc. (0000890821) (Issuer)

    9/19/23 5:34:00 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

    Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases. The term sheets c

    3/19/24 7:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer, effective March 13, 2023. Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies. As CFO, Mr. Coveney will be responsibl

    2/28/23 7:30:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/13/24 11:18:03 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/12/24 1:43:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ENVB
    Financials

    Live finance-specific insights

    View All

    Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

    Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe

    3/26/24 7:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

    Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded company; Enveric now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of

    5/15/23 9:25:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

    The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC') for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences, Inc. (‘Akos'),

    11/28/22 7:30:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care